The TGF-β co-receptor endoglin modulates the expression and transforming potential of H-Ras

Carcinogenesis

Volumn 31, Issue 12, 2010, Pages 2145-2154

  Santibanez, Juan F ^a,b,f   Pérez Gómez, Eduardo ^c   Fernandez L, Africa ^a   Garrido Martin, Eva M ^a   Carnero, Amancio ^d   Malumbres, Marcos ^d   Vary, Calvin P H ^e   Quintanilla, Miguel ^c   Bernabéu, Carmelo ^a  

^a CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

^b UNIVERSITY OF CHILE   (Chile)

^c UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^d Centro Nacional de Investigaciones Oncológicas   (Spain)

^e Maine Medical Center Research Institute   (United States)

^f UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOGLIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN C FOS; RAS PROTEIN; SMAD4 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL CELL; ARTICLE; CARCINOGENESIS; CARCINOMA CELL; CELL STRAIN 3T3; CELL TRANSFORMATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; EPIDERMIS CELL; GENE ACTIVATION; GENE EXPRESSION; GENE TARGETING; KERATINOCYTE; MOUSE; NONHUMAN; ONCOGENE H RAS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SPINDLE CELL; TRANSACTIVATION;

EID: 78649785000     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgq199     Document Type: Article

References (58)

1. Fonsatti,E. et al. (2003) Endoglin (CD105): a powerful therapeutic target on tumor-associated angiogenetic blood vessels. Oncogene, 22, 6557-6563.
2. Bernabeu,C. et al. (2007) Novel biochemical pathways of endoglin in vascular cell physiology. J. Cell. Biochem., 102, 1375-1388.
3. Bernabeu,C. et al. (2009) The emerging role of TGF-b superfamily coreceptors in cancer. Biochim. Biophys. Acta, 1792, 954-973.
4. Liu,Y. et al. (2002) Over expression of endoglin in human prostate cancer suppresses cell detachment, migration and invasion. Oncogene, 21, 8272-8281.
5. Craft,C.S. et al. (2007) Endoglin inhibits prostate cancer motility via activation of the ALK2-Smad1 pathway. Oncogene, 26, 7240-7250.
6. Pérez-Gómez,E. et al. (2007) A role for endoglin as a suppressor of malignancy during mouse skin carcinogenesis. Cancer Res., 67, 10268-10277.
7. Quintanilla,M. et al. (1986) Carcinogen-specific mutation and amplification of Ha-ras during mouse skin carcinogenesis. Nature, 322, 78-80.
8. Buchmann,A. et al. (1991) Progression of squamous carcinoma cells to spindle carcinomas of mouse skin is associated with an imbalance of H-ras alleles on chromosome 7. Cancer Res., 51, 4097-4101.
9. Rodriguez-Puebla,M.L. et al. (1999) Increased expression of mutated Ha-ras during premalignant progression in SENCAR mouse skin. Mol. Carcinog., 26, 150-156.
10. Caulin,C. et al. (1995) Chronic exposure of cultured transformed mouse epidermal cells to transforming growth factor-beta 1 induces an epithelial-mesenchymal transdifferentiation and a spindle tumoral phenotype. Cell Growth Differ., 6, 1027-1035.
11. Cui,W. et al. (1996) TGFbeta1 inhibits the formation of benign skin tumors, but enhances progression to invasive spindle carcinomas in transgenic mice. Cell, 86, 531-542.
12. Lebrin,F. et al. (2004) Endoglin promotes endothelial cell proliferation and TGF-b/ALK1 signal transduction. EMBO J., 23, 4018-4028.
13. Quintanilla,M. et al. (2003) Expression of the TGF-beta coreceptor endoglin in epidermal keratinocytes and its dual role in multistage mouse skin carcinogenesis. Oncogene, 22, 5976-5985.
14. Pérez-Gómez,E. et al. (2005) Characterization of murine S-endoglin isoform and its effects on tumor development. Oncogene, 24, 4450-4461.
15. Quintanilla,M. et al. (1991) Comparison of ras activation during epidermal carcinogenesis in vitro and in vivo. Carcinogenesis, 12, 1875-1881.
16. Burns,P.A. et al. (1991) Loss of heterozygosity and mutational alterations of the p53 gene in skin tumours of interspecific hybrid mice. Oncogene, 6, 2363-2369.
17. Conley,B.A. et al. (2004) Endoglin controls cell migration and composition of focal adhesions: function of the cytosolic domain. J. Biol. Chem., 279, 27440-27449.
18. Guerrero-Esteo,M. et al. (2002) Extracellular and cytoplasmic domains of endoglin interact with the transforming growth factor-beta receptors I and II. J. Biol. Chem., 277, 29197-29209.
19. Feig,L.A. et al. (1988) Relationship among guanine nucleotide exchange, GTP hydrolysis, and transforming potential of mutated ras proteins. Mol. Cell. Biol., 8, 2472-2478.
20. Labbe,E. et al. (1998) Smad2 and Smad3 positively and negatively regulate TGF-beta-dependent transcription through the forkhead DNA-binding protein FAST2. Mol. Cell, 2, 109-120.
21. Conley,B.A. et al. (2004) Endoglin controls cell migration and composition of focal adhesions. J. Biol. Chem., 279, 27440-27449.
22. Mikheev,A.M. et al. (2000) CArG binding factor A (CBF-A) is involved in transcriptional regulation of the rat Ha-ras promoter. Nucleic Acids Res., 28, 3762-3770.
23. Hu,Q. et al. (1995) Ras-dependent induction of cellular responses by constitutively active phosphatidylinositol-3 kinase. Science, 268, 100-102.
24. Dennler,S. et al. (1998) Direct binding of Smad3 and Smad4 to critical TGF beta-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene. EMBO J., 17, 3091-3100.
25. Santibanez,J.F. et al. (2007) Endoglin increases eNOS expression by modulating Smad2 protein levels and Smad2-dependent TGF-beta signaling. J. Cell. Physiol., 210, 456-468.
26. Iglesias,M. et al. (2000) Blockade of Smad4 in transformed keratinocytes containing a Ras oncogene leads to hyperactivation of the Ras-dependent Erk signalling pathway associated with progression to undifferentiated carcinomas. Oncogene, 19, 4134-4145.
27. Bellon,T. et al. (1993) Identification and expression of two forms of the human transforming growth factor-beta-binding protein endoglin with distinct cytoplasmic regions. Eur. J. Immunol., 23, 2340-2345.
28. Sukumar,S. et al. (1988) Independent molecular pathways in initiation and loss of hormone responsiveness of breast carcinomas. Science, 240, 524-526.
29. Oft,M. et al. (2002) Metastasis is driven by sequential elevation of H-ras and Smad2 levels. Nat. Cell. Biol., 4, 487-494.
30. Derynck,R. et al. (2003) Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature, 6958, 577-584.
31. Bremner,R. et al. (1990) Genetic changes in skin tumor progression: correlation between presence of a mutant ras gene and loss of heterozygosity on mouse chromosome 7. Cell, 61, 407-417.
32. Zoumpourlis,V. et al. (2003) Alterations in signal transduction pathways implicated in tumour progression during multistage mouse skin carcinogenesis. Carcinogenesis, 24, 1159-1165.
33. Der,C.J. et al. (1986) Biological and biochemical properties of human rasH genes mutated at codon 61. Cell, 44, 167-176.
34. Frontelo,P. et al. (1998) Transforming growth factor beta 1 induces squamous carcinoma cell variants with increased metastatic abilities and a disorganized cytoskeleton. Exp. Cell Res., 244, 420-432.
35. Santibanez,J.F. et al. (1999) Urokinase expression and binding activity associated with the transforming growth factor beta1-induced migratory and invasive phenotype of mouse epidermal keratinocytes. J. Cell. Biochem., 74, 61-73.
36. Xie,L. et al. (2004) Activation of the Erk pathway is required for TGF-beta1-induced EMT in vitro. Neoplasia, 6, 603-610.
37. Yue,J. et al. (2000) Requirement of Ras/MAPK pathway activation by transforming growth factor beta for transforming growth factor beta 1 production in a smad-dependent pathway. J. Biol. Chem., 275, 30765-30773.
38. Fink,S.P. et al. (2003) TGF-beta-induced nuclear localization of Smad2 and Smad3 in Smad4 null cancer cell lines. Oncogene, 22, 1317-1323.
39. Santibanez,J.F. et al. (2000) Involvement of the Ras/MAPK signaling pathway in the modulation of urokinase production and cellular invasiveness by transforming growth factor-beta(1) in transformed keratinocytes. Biochem. Biophys. Res. Commun., 273, 521-527.
40. Santibanez,J.F. et al. (2002) Transforming growth factor-beta1 modulates matrix metalloproteinase-9 production through the Ras/MAPK signaling pathway in transformed keratinocytes. Biochem. Biophys. Res. Commun., 296, 267-273.
41. Wasylyk,B. et al. (1998) Ets transcription factors: nuclear effectors of the Ras-MAP-kinase signalling pathway. Trends Biochem. Sci., 23, 213-216.
42. Yordy,J.S. et al. (2000) Signal transduction and the Ets family of transcription factors. Oncogene, 19, 6503-6513.
43. Lu,J. et al. (1994) Start site selection by Sp1 in the TATA-less human Ha-ras promoter. J. Biol. Chem., 269, 5391-5402.
44. Kwak,H.J. et al. (2006) Transforming growth factor-beta1 induces tissue inhibitor of metalloproteinase-1 expression via activation of extracellular signal-regulated kinase and Sp1 in human fibrosarcoma cells. Mol. Cancer Res., 4, 209-220.
45. Hartsough,M.T. et al. (1995) Transforming growth factor beta activation of p44mapk in proliferating cultures of epithelial cells. J. Biol. Chem., 270, 7117-7124.
46. Hartsough,M.T. et al. (1996) Altered transforming growth factor signaling in epithelial cells when ras activation is blocked. J. Biol. Chem., 271, 22368-22375.
47. Blanco,F.J. et al. (2005) Interaction and functional interplay between endoglin and ALK-1, two components of the endothelial transforming growth factor-beta receptor complex. J. Cell. Physiol., 204, 574-584.
48. Guo,B. et al. (2004) CD105 inhibits transforming growth factor-beta-Smad3 signalling. Anticancer Res., 24, 1337-1345.
49. Rodríguez-Barbero,A. et al. (2006) Endoglin modulation of TGF-beta1-induced collagen synthesis is dependent on ERK1/2 MAPK activation. Cell. Physiol. Biochem., 18, 135-142.
50. Lee,N.Y. et al. (2007) The interaction of endoglin with beta-arrestin2 regulates transforming growth factor-beta-mediated ERK activation and migration in endothelial cells. J. Biol. Chem., 282, 21507-21517.
51. Kretzschmar,M. et al. (1999) A mechanism of repression of TGFbeta/Smad signaling by oncogenic Ras. Genes Dev., 13, 804-816.
52. Funaba,M. et al. (2002) Modulation of Smad2-nediated signalling by extracellular signal-regulated kinase. J. Biol. Chem., 277, 41361-41368.
53. Arany,P.R. et al. (2008) Smad3 deficiency inhibits v-ras-induced transformation by suppression of JNK MAPK signaling and increased farnesyl transferase inhibition. Oncogene, 27, 2507-2512.
54. Owens,D.M. et al. (2007) Differential regulation of MAP kinase signalling by dual-specificity protein phosphatases. Oncogene, 26, 3203-3213.
55. Lastres,P. et al. (1994) Phosphorylation of the human-transforming-growth-factor-beta-binding protein endoglin. Biochem. J., 301, 765-768.
56. Koleva,R.I. et al. (2006) Endoglin structure and function: determinants of endoglin phosphorylation by transforming growth factor-beta receptors. J. Biol. Chem., 281, 25110-25123.
57. Zuo,W. et al. (2009) Specific activation of mitogen-activated protein kinase by transforming growth factor-b receptors in lipid rafts is required for epithelial cell plasticity. Mol. Biol. Cell., 20, 1020-1029.
58. Kemp,C.J. (2005) Multistep skin cancer in mice as a model to study the evolution of cancer cells. Semin. Cancer Biol., 15, 460-473.